Press Releases

Date Title and Summary Additional Formats
Toggle Summary Biocept and UC San Diego Moores Cancer Center Announce Collaboration to Study Feasibility of Liquid Biopsy to Predict Disease Recurrence in Solid Tumors and Response to Therapy
Clinical studies with Biocept's Target Selector™ to evaluate the use of circulating tumor cells in disease assessment, surveillance and monitoring SAN DIEGO , July 23, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide
View HTML
Toggle Summary Biocept Reminds Investors of Today's Deadline to be a Shareholder of Record
To be a shareholder of record, investors are advised to own Biocept stock by 4:00 PM ET, Thursday, July 19, 2018 to account for T+2 settlement timing Record date established as Monday, July 23, 2018 SAN DIEGO , July 19, 2018 /PRNewswire/ -- Biocept, Inc.
View HTML
Toggle Summary Biocept Enters into Agreement with Alliance Global FZ to Market and Distribute Liquid Biopsy Testing in the Middle East, Southeast Asia, and Africa Region
Expands international distribution of Target Selector™ platform to 17 countries SAN DIEGO , July 13, 2018 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes
View HTML
Toggle Summary Biocept Informs Stockholders of Key Dates and Terms Related to Announced Rights Offering
SAN DIEGO , July 11, 2018 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC) (" Biocept "), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, today provided an
View HTML
Toggle Summary Biocept Highlights Recent Progress and Outlines Near-Term Strategic Priorities in CEO Letter to Stockholders
SAN DIEGO , June 25, 2018 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that President and CEO Michael W.
View HTML
Toggle Summary Published Case Report Demonstrates the Clinical Utility of Biocept's CTC Platform in the Management of Patients with Metastatic Breast Cancer
Peer-reviewed article in journal Clinics in Oncology highlights ability of Biocept's Target Selector™ to detect a key biomarker to qualify breast cancer patients for targeted therapy when tissue biopsy is inconclusive SAN DIEGO , June 18, 2018 /PRNewswire/ --  Biocept, Inc.
View HTML
Toggle Summary VWR, Part of Avantor, and Biocept Announce the Launch of CEE-Sure Blood Collection Tubes for cfDNA and CTCs
Biocept's patented collection tubes now available from VWR for the safe transport of patient specimens containing both circulating cell-free DNA (cfDNA) and circulating tumor cells (CTCs) at room temperature SAN DIEGO , June 11, 2018 /PRNewswire/ --  Biocept, Inc .
View HTML
Toggle Summary Biocept to Present at the 8th Annual LD Micro Invitational Conference on June 5
SAN DIEGO , May 29, 2018 /PRNewswire/ --  Biocept, Inc.  (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing proprietary liquid biopsy tests that provide clinically actionable information to physicians to improve cancer treatment, announces that President and CEO Michael
View HTML
Toggle Summary Biocept Reports First Quarter 2018 Financial Results
Company to host conference call at 4:30 p.m. Eastern time today SAN DIEGO , May 15, 2018 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer
View HTML
Toggle Summary Biocept to Release First Quarter 2018 Financial Results and Host Investor Conference Call on May 15, 2018
SAN DIEGO , May 8, 2018 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing proprietary liquid biopsy tests that provide clinically actionable  information to physicians to improve cancer treatment, announces that it will release financial
View HTML